Masked hypertension was associated with increased risk of myocardial infarction (OR 5.062; 95% CI 2.218-11.550; P<.001), while both masked and white-coat hypertension increased heart failure risk.
Cohort (n=2,209)
Do white-coat hypertension and masked hypertension increase the risk of cardiovascular events compared to normotension in adult untreated individuals?
Both white-coat and masked hypertension are associated with significantly increased long-term risks of cardiovascular events, including heart failure and myocardial infarction, compared to normotension.
Effect estimate: OR 5.062 (95% CI 2.218-11.550)
p-value: p=<.001
The aim of this study was to analyze prevalence and clinical outcomes of the following clinical conditions: normotension (NT; clinic BP < 140/90 mm Hg; 24-hour BP < 130/80 mm Hg), white-coat hypertension (WCHT; clinic BP ≥ 140 and/or ≥90 mm Hg; 24-hour BP < 130/80 mm Hg), masked hypertension (MHT; clinic BP < 140/90 mm Hg; 24-hour BP ≥ 130 and/or ≥80 mm Hg), and sustained hypertension (SHT; clinic BP ≥ 140 and/or ≥90 mm Hg; 24-hour BP ≥ 130 and/or ≥80 mm Hg) in a large cohort of adult untreated individuals. Systematic research throughout the medical database of Regione Lazio (Italy) was performed to estimate incidence of myocardial infarction (MI), stroke, and hospitalizations for HT and heart failure (HF). Among a total study sample of 2209 outpatients, 377 (17.1%) had NT, 351 (15.9%) had WCHT, 149 (6.7%) had MHT, and 1332 had (60.3%) SHT. During an average follow-up of 120.1 ± 73.9 months, WCHT was associated with increased risk of hospitalization for HT (OR 95% CI: 1.927 1.233-3.013; P = .04) and HF (OR 95% CI: 3.449 1.321-9.007; P = .011). MHT was associated with an increased risk of MI (OR 95% CI: 5.062 2.218-11.550; P < .001), hospitalization for HT (OR 95% CI: 2.553 1.446-4.508; P = .001), and for HF (OR 95% CI: 4.214 1.449-12.249; P = .008). These effects remained statistically significant event after corrections for confounding factors including age, BMI, gender, smoking, dyslipidaemia, diabetes, and presence of antihypertensive therapies.
Tocci et al. (Thu,) conducted a cohort in White-coat and masked hypertension (n=2,209). White-coat and masked hypertension vs. Normotension was evaluated on Myocardial infarction (MI), stroke, and hospitalizations for HT and heart failure (HF) (OR 5.062, 95% CI 2.218-11.550, p=<.001). Masked hypertension was associated with increased risk of myocardial infarction (OR 5.062; 95% CI 2.218-11.550; P<.001), while both masked and white-coat hypertension increased heart failure risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: